AlphAIalphai — Financial news for AI agents
stocktitan.netJUL 293 min read$CLVT

Clarivate (NYSE: CLVT) promotes Michael Easton to CFO role

Clarivate Plc (NYSE: CLVT) filed an 8-K. CFO Jonathan Collins resigned effective Aug. 7, 2026. Clarivate appointed Michael Easton as Executive Vice President and CFO effective Aug. 8, 2026, with $600,000 base salary and 2027 equity grant targeted at $2.0M. Matthew Lisowski was appointed Chief Accounting Officer effective Aug. 8, 2026.

Original reporting
stocktitan.net
Published Jul 29, 2026, 8:31 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 30, 2026, 4:42 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$CLVT
Neutral
medium confidence
Mentioned
$CLVT
Relevance
5/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$CLVTNeutralLow
01

Why it matters

The main tradable element is the leadership transition timeline and the fact that it is not attributed to disagreements or auditor issues.

02

Market read

This is a primary-source executive change disclosure with compensation terms, but no new earnings, guidance, or material business event.

03

What to watch

Compensation structure and internal promotion path may matter more than the headline, but the article does not disclose any turnaround plan or accounting risk.

Relevance 5/10Novelty 5/10Timing: effective Aug. 7-8, 2026 CFO transition

Background

The company filed an 8-K describing CFO and Chief Accounting Officer promotions effective Aug. 8, 2026.

Company-level read

Ticker impact

$CLVTNeutralMedium confidence
Context

Clarivate appointed Michael Easton as CFO effective Aug. 8, 2026, following Jonathan Collins’ resignation effective Aug. 7.

Expected impact

Likely limited near-term impact unless investors interpret the transition as a change in financial strategy or controls.

Evidence & confidence

The article is an 8-K officer appointment with compensation details, not a performance update, forecast, or material transaction.

Market effects

Sector

Minimal direct read-through to the broader software and information services sector without any guidance or product change.

Regional

Primarily US-listed governance news for a UK-domiciled issuer; limited regional spillover.

Global

Low global relevance absent any international contract, regulatory action, or financial forecast change.

Counterpoint

What could challenge this read

Investors may overreact to the CFO change; absent new targets or restatements, the market impact should be muted.

Key entities

  • company
    Clarivate Plc

    NYSE-listed company that announced CFO and Chief Accounting Officer appointments via an 8-K.

  • executive
    Michael Easton

    Appointed Executive Vice President and CFO effective Aug. 8, 2026; previously SVP Finance and Chief Accounting Officer.

  • executive
    Jonathan Collins

    Resigned as CFO effective Aug. 7, 2026; resignation not linked to disagreements.

  • executive
    Matthew Lisowski

    Appointed Senior Vice President and Chief Accounting Officer effective Aug. 8, 2026.

Read at source← All news

Related articles

JUL 29
$CLVTMed

Clarivate Plc Q2 2026 Earnings Call Summary

Clarivate Plc (Q2 2026) discussed its Value Creation Plan to shift from transactional to recurring subscription revenue. It plans to divest the Life Sciences & Healthcare segment by year-end 2026, targeting about 92% recurring revenue pro forma. Management cited a $269m non-cash impairment, $70m one-time costs, and expects low-end FCF due to transaction and restructuring costs.

yahoo.com6 min
JUL 29
$CLVTMed

Clarivate Reports Second Quarter 2026 Results

Clarivate Plc (NYSE: CLVT) reported Q2 2026 results for the quarter ended June 30. Total revenue fell to $587.3 million from $621.4 million a year earlier, while organic revenues declined 1.5%. Net loss widened to $268.6 million due to a $221.7 million goodwill impairment; adjusted net income was $123.1 million. The company reaffirmed its 2026 outlook and cited a Life Sciences & Healthcare divestiture.

prnewswire.com6 min
JUL 29
$CLVTMedAI 8/10

CLARIVATE PLC (CLVT): Results of Operations and Financial Condition

CLARIVATE PLC (CLVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991q22026earningsrelease.htm EX-99.1 Ex. 99.1 Q2 2026 Earnings Release 1 Clarivate Reports Second Quarter 2026 Results — Delivers continued progress on strategic and financial priorities through Value Creation Plan — — Sharpens focus and enhances financial profile wit

SEC EDGAR 8-K4 min
JUL 12
$CLVTMedAI 8/10

Clarivate to Sell Life Sciences Unit to Altaris for $600M, Refocus Core Business

Clarivate (NYSE:CLVT) will sell its Life Sciences & Healthcare unit to Altaris for $600M to refocus on Academia & Government and Intellectual Property, according to company executives. Clarivate affirmed 2026 guidance midpoints except free cash flow, citing added transaction costs. Pro forma revenue and adjusted EBITDA would be down about $370M and $120M, but free cash flow is expected to hold.

yahoo.com5 min